Catalent Inc. (Somerset, NJ) is a global CDMO. 2024 revenue ~$4.4B. Drug delivery, gene therapy, biologics manufacturing. Acquired by Novo Holdings (2024) — ties to Novo Nordisk GLP-1 supply. Fill-finish and oral solid dose.
12:41:33 AM · Jul 9, 2026